MARKET

HAE

HAE

Haemonetics Corp Mass
NYSE
85.35
+1.26
+1.50%
After Hours: 85.35 0 0.00% 16:00 03/28 EDT
OPEN
83.92
PREV CLOSE
84.09
HIGH
85.45
LOW
83.67
VOLUME
593.88K
TURNOVER
0
52 WEEK HIGH
95.26
52 WEEK LOW
70.74
MARKET CAP
4.33B
P/E (TTM)
34.54
1D
5D
1M
3M
1Y
5Y
Is Haemonetics Corporation's (NYSE:HAE) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Haemonetics (NYSE:HAE) has a return on equity of 13% and a decent earnings growth rate of 14%. We look at the company's ROE to compare it to its industry average. Haemonetics has a respectable 13% return on Equity. The company has grown its net income growth over the last five years. The stock is up 9.2% for the last month. Haemonetic is reinvesting heavily into its business.
Simply Wall St · 3d ago
Weekly Report: what happened at HAE last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at HAE last week (0311-0315)?
Weekly Report · 03/18 09:02
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
NASDAQ · 03/11 13:30
Weekly Report: what happened at HAE last week (0304-0308)?
Weekly Report · 03/11 09:02
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Haemonetics Corporation's (NYSE:HAE) estimated fair value is US$120 based on 2 Stage Free Cash Flow to Equity. Haemonetics' US$77.45 share price signals that it might be 35% undervalued. We will use a discounted cash flow model to estimate the company's intrinsic value. The company is valued at 35% below its current share price.
Simply Wall St · 03/07 12:19
Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Haemonetics Corporation has announced a deal to acquire Attune Medical in a $160 million cash deal. Haemonetics has seen improvements in its business after a tough period during the pandemic. The company's share price has lagged, but the company's adjusted earnings multiples have fallen below 20 times. The blood player announced another bolt-on acquisition in March 2024.
Seeking Alpha · 03/06 22:38
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
NASDAQ · 03/06 11:54
More
About HAE
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.

Webull offers Haemonetics Corporation stock information, including NYSE: HAE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HAE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HAE stock methods without spending real money on the virtual paper trading platform.